The moment represents a historic milestone for both the company and the local financial ecosystem, confirming the maturity of the capital market and the development potential of the private medical system. Reaching this symbolic threshold comes in a context marked by economic volatility and uncertainties, underlining the resilience of MedLife’s business model and the strategic relevance of the medical sector. The evolution of the company’s shares reflects investors’ confidence in a strategy geared towards sustainable growth and operational performance.
Nine years after the listing on December 16, 2016, MedLife marks a path built on transparency, accountability and solid investments. During this period, the company has carried out one of the largest expansion programs in the Romanian private sector, consolidating over 60 acquisitions and developing a nationwide integrated medical platform.
In parallel, MedLife has consistently invested in technology, AI, robots, drones and medical teams, helping to increase access to modern healthcare services for millions of patients. At the same time, the company has played an essential role in the Romanian capital market ecosystem, setting new standards of transparency, reporting and corporate governance.
“Reaching the EUR 1 billion capitalization threshold is an important validation for us and proof that the MedLife model remains solid and relevant, regardless of the context. It is the result of consistent work over three decades and the trust that our investors, partners and colleagues have placed in us. We thank everyone for being part of this evolution. We are going through a complex period, with economic, social and geopolitical pressures. However, we believe that, with the implementation of the latest public policies at national level, Romania has the chance to move in the right direction. As far as we are concerned, we remain focused on investments in innovation and medical research: genomics, artificial intelligence – especially in imaging and laboratory, the development of prevention programs and the continuation of personalized medicine projects.
We strongly believe that the training and quality of the MedLife medical staff have helped us to consolidate our position as a leader in Romanian private medicine, and by transforming it into a medical technology company we have become an important player in innovation not only in Romania, but also in the region. On the other hand, it is not to be neglected that, amid a significant budget deficit and the inherent measures of the central government to reduce it in recent months, retail sales have fallen during this period according to INS figures, and will probably continue to decline at the end of this year. And, in the same context, the private medical sector has slightly slowed its growth. However, I have no doubt that, gradually, perhaps even starting with the second quarter of next year, we will have an important chance to resume sustainable growth,” said Mihai Marcu, President and CEO of MedLife Group.
MedLife had total assets of RON466 million in 2016, compared to over RON3 billion in 2024, and its turnover increased over fivefold during this period, to RON2.72 billion in 2024 from RON502 million in 2016. Its network consists of over 450 own medical units.
Medlife shares have traded 68% higher so far in 2025, amid deals worth RON271 million.